April 1 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:
CONNECT BIOPHARMA ANNOUNCES POSITIVE TYPE C MEETING WITH THE FDA FOR RADEMIKIBART
CONNECT BIOPHARMA HOLDINGS LTD - TRIALS EXPECTED TO INITIATE IN Q2 2025
CONNECT BIOPHARMA HOLDINGS LTD - DATA FROM RADEMIKIBART PHASE 2 TRIALS EXPECTED IN H1 2026
Source text: ID:nGNX6n7CSX
Further company coverage: CNTB.O
(((( Reuters.briefs@thomsonreuters.com ;));))